Evaluation of factors predicting the effectiveness of regorafenib in the treatment of metastatic colorectal cancer

Basit Öğe Kaydı
dc.authorid0000-0002-0878-6525en_US
dc.authorid0000-0002-7931-2941en_US
dc.authorid0000-0003-3878-988Xen_US
dc.authorid0000-0001-7858-8180en_US
dc.authorid0000-0003-0882-0524en_US
dc.authorid0000-0001-7336-871Xen_US
dc.authorid0000-0002-7451-7286en_US
dc.contributor.authorEbinç, Senar
dc.contributor.authorOruç, Zeynep
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorKalkan, Ziya
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorKüçüköner, Mehmet
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.date.accessioned2024-01-29T11:06:08Z
dc.date.available2024-01-29T11:06:08Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractObjective: Regorafenib is a multikinase inhibitor, the effectiveness of which was demonstrated in metastatic colorectal cancer. This study aimed to investigate the factors that could predict the effectiveness of regorafenib. Materials and Methods: This study retrospectively reviewed the clinical characteristics, tumor characteristics, and previous therapies in 62 patients who presented to our center between 2016 and 2020 and used regorafenib for metastatic colorectal cancer. The effects of the investigated variables on the response obtained with regorafenib use were evaluated. Results: This study included a total of 62 patients diagnosed with metastatic colorectal cancer, of whom 30 (48.4%) were males and 32 (51.6%) were females. Patients' median age at diagnosis was 49 years (1868). Regorafenib therapy yielded a disease control rate of 64% [complete response = 0, partial response= 14 (28%), and stable disease = 18 (36%)]. Objective response was obtained in 28% of patients [complete response = 0 and partial response = 14 (28%)]. Progression-free survival was 4 months. The evaluation of the effects of patients' age, sex, performance status, previous treatments, metastatic sites, and RAS mutation status on the disease control rate and progression-free survival did not determine any positive or negative effects on progression-free survival. However, left-sided tumors had a positive effect on disease control rate (69.8% vs. 28.6%, P =.029). and previous use of cetuximab had a negative effect on disease control rate [76.5% vs. 37.5% (P =.007)]. Conclusion: In our study, tumor localization and previous cetuximab use were found to be correlated with the disease control rate in patients on regorafenib. However, the need for novel biomarkers that will predict the effectiveness of regorafenib in metastatic colorectal cancer treatment persists.en_US
dc.identifier.citationEbinç, S., Oruç, Z., Urakçı, Z., Kalkan, Z., Kaplan, M. A., Küçüköner, M. ve diğerleri. (2022). Evaluation of factors predicting the effectiveness of regorafenib in the treatment of metastatic colorectal cancer. Eurasian Journal of Medicine, 54(3), 229-234.en_US
dc.identifier.doi10.5152/eurasianjmed.2022.21162
dc.identifier.endpage234en_US
dc.identifier.issn1308-8734
dc.identifier.issue3en_US
dc.identifier.pmid35950825
dc.identifier.scopus2-s2.0-85140270849
dc.identifier.scopusqualityQ2
dc.identifier.startpage229en_US
dc.identifier.trdizinid1167017
dc.identifier.urihttps://www.eajm.org//en/evaluation-of-factors-predicting-the-effectiveness-of-regorafenib-in-the-treatment-of-metastatic-colorectal-cancer-133411%5C
dc.identifier.urihttps://hdl.handle.net/11468/13299
dc.identifier.volume54en_US
dc.identifier.wosWOS:000891602000005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorEbinç, Senar
dc.institutionauthorOruç, Zeynep
dc.institutionauthorUrakçı, Zuhat
dc.institutionauthorKalkan, Ziya
dc.institutionauthorKaplan, Muhammet Ali
dc.institutionauthorKüçüköner, Mehmet
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.language.isoenen_US
dc.publisherAves Yayıncılıken_US
dc.relation.ispartofEurasian Journal of Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCanceren_US
dc.subjectColonen_US
dc.subjectRegorafeniben_US
dc.titleEvaluation of factors predicting the effectiveness of regorafenib in the treatment of metastatic colorectal canceren_US
dc.titleEvaluation of factors predicting the effectiveness of regorafenib in the treatment of metastatic colorectal cancer
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer.pdf
Boyut:
705.2 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu